Journal
CANCER CELL
Volume 28, Issue 1, Pages 57-69Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2015.06.002
Keywords
-
Categories
Funding
- GlaxoSmithKline
- Flight Attendants Medical Research Institute (FAMRI) Center of Excellence (or Center of Excellence at Johns Hopkins)
- Alex Grass Foundation
Ask authors/readers for more resources
Epigenetic dysregulation has emerged as an important mechanism in cancer. Alterations in epigenetic machinery have become a major focus for targeted therapies. The current report describes the discovery and biological activity of a cyclopropylamine containing inhibitor of Lysine Demethylase 1 (LSD1), GSK2879552. This small molecule is a potent, selective, orally bioavailable, mechanism-based irreversible inactivator of LSD1. A proliferation screen of cell lines representing a number of tumor types indicated that small cell lung carcinoma (SCLC) is sensitive to LSD1 inhibition. The subset of SCLC lines and primary samples that undergo growth inhibition in response to GSK2879552 exhibit DNA hypomethylation of a signature set of probes, suggesting this may be used as a predictive biomarker of activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available